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Abstract
Background—Genome-wide association studies (GWAS) have so far reported 12 loci 
associated with serous epithelial ovarian cancer (EOC) risk. We hypothesized that some of these 
loci function through nearby transcription factor (TF) genes and that putative target genes of these 
TFs as identified by co-expression may also be enriched for additional EOC risk associations.
Methods—We selected TF genes within 1 Mb of the top signal at the 12 genome-wide 
significant risk loci. Mutual information, a form of correlation, was used to build networks of 
genes strongly co-expressed with each selected TF gene in the unified microarray data set of 489 
serous EOC tumors from The Cancer Genome Atlas. Genes represented in this data set were 
subsequently ranked using a gene-level test based on results for germline SNPs from a serous 
EOC GWAS meta-analysis (2,196 cases/4,396 controls).
Results—Gene set enrichment analysis identified six networks centered on TF genes (HOXB2, 
HOXB5, HOXB6, HOXB7 at 17q21.32 and HOXD1, HOXD3 at 2q31) that were significantly 
enriched for genes from the risk-associated end of the ranked list (P<0.05 and FDR<0.05). These 
results were replicated (P<0.05) using an independent association study (7,035 cases/21,693 
controls). Genes underlying enrichment in the six networks were pooled into a combined network.
Conclusion—We identified a HOX-centric network associated with serous EOC risk containing 
several genes with known or emerging roles in serous EOC development.
Impact—Network analysis integrating large, context-specific data sets has the potential to offer 
mechanistic insights into cancer susceptibility and prioritize genes for experimental 
characterization.
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Introduction
The genetic architecture of inherited susceptibility to epithelial ovarian cancer (EOC) 
appears similar to other hormone-related cancers, but fewer EOC risk loci have been 
discovered compared to breast and prostate cancer, probably due to restricted sample size 
(1). Genome-wide association studies (GWAS) have so far identified 12 risk loci associated 
with serous EOC, the most common subtype of EOC (1–7). These account for 4 per cent of 
the excess familial risk of EOC, while rare, high-penetrance mutations in genes such as 
BRCA1 and BRCA2 explain about 40 per cent (8). This suggests that many undiscovered 
common serous EOC risk variants exist.
Very stringent statistical thresholds are generally used to declare common variant 
susceptibility alleles at so-called genome-wide significance (P < 5×10−8). However, when 
there is limited statistical power, hundreds or thousands of single nucleotide polymorphisms 
(SNPs) with small effect sizes will not reach genome-wide significance (9). A key challenge 
in genetic epidemiology is to identify these risk SNPs with small effects. One approach is 
ever-larger studies allied to better coverage of common variation across the genome to 
increase statistical power. However, even a case-control study with 100,000 samples has just 
23 per cent power to detect at genome-wide significance an allele of frequency 5 per cent 
that confers a per-allele relative risk of 1.1.
GWAS pathway analysis has emerged as a complement to imputation, single-variant testing 
and meta-analysis for the discovery of true genetic associations in the pool of SNPs that are 
below genome-wide significance (10). Pathway studies are guided by the hypothesis that 
true risk associations are more likely to cluster in genes that share a common biological 
function potentially dysregulated in disease pathogenesis. However, incomplete annotation 
and canonical representation of pathways in the literature are major limiting factors (11).
One approach to overcome this limitation is by analyzing GWAS signals within the reduced 
search space of dynamic networks constructed from pairwise interactions observed in large, 
independent, tissue-specific transcriptomic data sets (12). Further, GWAS of cancer and 
other diseases increasingly suggest that at least some genome-wide significant risk loci act 
through nearby transcription factor (TF) genes (13–15). Target genes of these TFs in turn 
have been found to be enriched for SNPs that fail to reach genome-wide significance but are 
nominally associated with the disease (16,17). Therefore, we adopted a risk locus TF gene-
centric approach to integrating serous EOC transcriptomic and GWAS data sets. Seven of 
the 12 known genome-wide significant serous EOC risk loci harbor at least one TF gene in 
the 2 Mb interval centered on the top SNP at the locus. This includes nine members of the 
HOXD cluster and 10 members of the HOXB cluster at the 2q31 and 17q21.32 loci, 
respectively. The target genes of most homeobox (HOX) TFs remain largely unknown due 
to their promiscuous DNA binding properties in vitro (18). Since genes highly co-expressed 
with TF genes are more likely to represent their targets (19), and co-expression has been 
linked to shared function (20), we used the genes highly co-expressed with each TF in The 
Cancer Genome Atlas (TCGA) high-grade serous EOC microarray data set to build hub-
and-spoke type TF-target gene networks (21). We then systematically interrogated these 
networks for overrepresentation of genes containing SNPs ranked high for their association 
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with serous EOC risk in a GWAS meta-analysis. Our aims were to prioritize hub TF genes 
whose networks demonstrated such overrepresentation as candidates for post-GWAS 
functional characterization and to use these networks to identify novel pathways and 
potential sub-genome-wide significant risk loci involved in serous EOC development. Most 
GWAS SNPs lie outside protein-coding regions of the genome and may affect cancer 
susceptibility by regulating a gene or genes up to a megabase away making such integrative 
genomic approaches to prioritizing genes in these 1 Mb regions imperative (22,23).
Materials and Methods
Ranking genes based on GWAS results for serous EOC risk
This study used P-values for association with serous EOC risk from a published meta-
analysis of a North American and UK GWAS for 2,508,744 SNPs that were either 
genotyped or imputed in a total of 2,196 serous EOC cases and 4,396 controls (1). The meta-
analysis was restricted to subjects of European descent and the HapMap II (release 22) CEU 
panel served as reference for imputation. The North American and UK GWAS together with 
the replication data set described below are summarized in Supplementary Table S1. All 
participants provided written informed consent and each contributing study was approved by 
the appropriate local institutional ethical review board. A complete list of genes annotated 
with start and end positions of each gene was downloaded via the Bioconductor package 
TxDb.Hsapiens.UCSC.hg19.knownGene (v2.8.0). After removing genes with ambiguous 
location, all SNPs were mapped to genes with boundaries defined by the start and end 
positions. The genes were ranked in descending order of the negative logarithm (base 10) of 
the minimum P-value among all SNPs in each gene after adjusting this P-value for the 
number of SNPs in the gene using a modification of the Sidak correction (24). This accounts 
for linkage disequilibrium (LD) between SNPs while reducing the effect of gene size on the 
minimum P-value (25). Pearson’s r between gene size and minimum P-value improved from 
−0.3 to +0.1. Adequacy of correction was further confirmed by quantile-quantile plots 
(Supplementary Figure S1). In all, 10,693 genes that were also represented in the TCGA 
gene expression data set (described below) were ranked based on the GWAS results for 
subsequent analysis.
Constructing serous EOC-specific co-expression networks with TF genes at risk loci as 
hubs
We selected genes with experimentally confirmed transcription factor activity as described 
in Vaquerizas et al. (26) that were less than 1 Mb from the most significant SNP at each of 
the 12 loci (1–7) known to be associated with serous EOC risk at genome-wide significance 
(Table 1). The SNPs listed in Table 1 were obtained from the Collaborative Oncological 
Gene-environment Study Primer (27). Nineteen of the 29 TF genes selected belonged to 
either the HOXB or the HOXD cluster. We relied on co-expression in serous EOC tissue to 
define possible context-specific target genes of the TFs.
Genes co-expressed with each selected TF gene were identified in the “unified expression” 
data set downloaded from TCGA (28). The data set contains expression measurements from 
three different microarray platforms unified into a single estimate for 11,864 genes in 489 
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high-grade serous ovarian adenocarcinoma samples (21). Four of the 29 TF genes were not 
represented in this data set and were therefore excluded. Co-expression was measured by 
mutual information (MI), a form of correlation, estimated using the adaptive partitioning 
method implemented in the Algorithm for the Reconstruction of Accurate Cellular Networks 
(ARACNE) (29). A threshold of P < 0.01 after Bonferroni correction for 11,864 pairwise 
tests was set in ARACNE to retain only the genes most strongly co-expressed with each TF 
gene.
Gene set enrichment analysis (GSEA)
Each TF gene and the genes co-expressed with it were treated as a single hub-and-spoke 
network. GSEA (30) was used to determine overrepresentation of genes from the serous 
EOC-associated end of the ranked list generated on the basis of the GWAS meta-analysis, in 
each network. Before evaluating each network by GSEA, its parent hub TF gene was 
excluded from the network. Ten thousand permutations were performed with the number 
increased to 50,000 for networks with P = 0 at 10,000. Genes in the ranked list that were not 
among the 11,864 genes in the TCGA data set were excluded before GSEA as their co-
expression with the TFs could not be evaluated. GSEA is optimized for gene sets/networks 
containing 15 to 500 genes (30). Applying this cut-off led to the exclusion of 11 of the 25 
networks from the primary GSEA. We also conducted a secondary GSEA run allowing for 
networks with more than 10 genes. This enabled evaluation of 24 out of the 25 co-
expression networks. Only the network centered on HOXD9 was excluded in the second 
GSEA run since it contained just six genes. Networks with GSEA P < 0.05 and FDR < 0.05 
were considered significant. We also reported fold enrichment as the ratio of the number of 
genes from the top 5% of the ranked list that were observed in each network to the number 
expected. Cytoscape (v2.8.3) was used for network visualization (31).
Replication analyses
First, we examined the effect of LD between SNPs in closely spaced genes. The frequent co-
expression of genes co-localized on the genome coupled with LD between SNPs in such 
genes has the potential to inflate the GSEA signal (25). We subjected all SNPs in genes that 
were in the ranked list input to GSEA to LD-based clumping using PLINK (v1.07) (32) and 
CEU LD information from HapMap II (release 22). Starting from the most significant SNP, 
all SNPs with r2 > 0.7 within 250 kb of it were removed and the step repeated for the next 
best available SNP. Using the LD-thinned SNP list, SNP-to-gene mapping, gene ranking and 
GSEA were repeated as described above.
Second, to replicate significant findings from our primary analysis, we used an independent 
data set from the Collaborative Oncological Gene-environment Study (COGS). The COGS 
data set included 7,035 serous EOC cases and 21,693 controls of European descent after 
exclusion of overlap with the samples used in the primary analysis (Supplementary Table 
S1). These were genotyped using the iCOGS custom array (1) and imputed into the 1000 
Genomes March 2012 EUR reference panel (Kuchenbaecker et al., under review). The 
imputed data set was filtered to retain 7,768,381 SNPs with minor allele frequency > 0.03 
for consistency with the GWAS meta-analysis. SNP-to-gene mapping (without LD-based 
clumping), gene ranking and GSEA were repeated as described above.
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Analysis of combined network
The “leading-edge” subsets of genes from all co-expression networks that were significant 
in the primary analysis were combined into a single network. The leading-edge subset is the 
core of a gene set or network that drives its enrichment signal. It is defined as those 
members of the network that are ranked higher than the position in the ranked gene list 
where the network enrichment score is maximum (30). Subsequent analyses were conducted 
on genes in the combined network.
First, we input the genes to the Disease Association Protein-Protein Link Evaluator 
(DAPPLE, v1.0) (33). DAPPLE uses a database of 169,810 well-established pairwise 
interactions between 12,793 proteins to connect input proteins (genes) directly or indirectly 
via a single protein not in the input. Biologically meaningful networks are more connected 
than random ones and DAPPLE tests the significance of indirect connectivity in the resultant 
network using permutation.
Second, we measured co-expression between each TF gene that was the hub of a significant 
network in the primary analysis and 17,255 other genes with expression levels profiled in 
the 245-sample Australian Ovarian Cancer Study (AOCS) serous EOC microarray data set 
(GSE9899) (34,35) using MI calculated by ARACNE. All 17,255 genes were ranked based 
on the strength of their co-expression with each hub TF. For each hub TF, we then counted 
the number of genes co-expressed with it in the combined network that were also observed 
among the top (strongest) 1% and top 10% of co-expression interactions for the TF in the 
AOCS data set as arbitrary estimates of tissue-specific replication of these co-expression-
derived interactions.
Third, we used PSCAN (v1.2.2) (36) to test overrepresentation of known TF binding motifs 
from TRANSFAC (Human) (37) up to 1 kb upstream of transcription start sites of genes in 
the combined network. HOXB and HOXD motifs were absent in PSCAN but some 
homeodomain motifs were represented.
Results
The network-based analytical strategy we used to integrate serous EOC GWAS and gene 
expression data sets is outlined in Figure 1. A total of 29 TF genes were located within 1 Mb 
of the top risk-associated SNP at seven of the 12 known genome-wide significant serous 
EOC risk loci (Table 1). Of these, four TFs were not represented in the TCGA data set used 
in this study and could not be evaluated further (Table 1). Computing pairwise mutual 
information between the somatic expression levels of each remaining TF gene (fixed as a 
hub) and the 11,863 other genes in the TCGA data set using an adaptive partitioning 
procedure with a Bonferroni-adjusted threshold of P < 0.01 to retain only the most strongly 
co-expressed genes yielded 25 hub-and-spoke type networks ranging in size from 6 to 1,953 
genes. Fourteen TF genes from five risk loci were hubs of co-expression networks that 
included between 17 and 368 genes placing them in the gene set size range (15 to 500 genes) 
optimal for GSEA (Tables 1 and 2). A total of 689,882 of the approximately 2.5 million 
SNPs from the serous EOC GWAS meta-analysis were located within the boundaries of 
10,693 of the 11,864 genes represented in the TCGA data. These genes were ranked in 
Kar et al. Page 5
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
descending order using the negative logarithm (base 10) of the modified Sidak-corrected 
minimum P-value among all SNPs in each gene.
Six of the 14 networks tested by GSEA (with hubs HOXB2, HOXB7, HOXB6, and HOXB5 
at 17q21.32, and hubs HOXD3 and HOXD1 at 2q31) were significantly enriched for genes 
that ranked high for their association with serous EOC risk (GSEA P < 0.05 and FDR < 
0.05; Table 2). The significant networks demonstrated between 1.5- and 8-fold enrichment 
for genes from the top 5% of the ranked list as compared to expectation (Table 2). 
Supplementary Table S2 lists the genes in each significant network.
The six networks identified by the primary analysis remained significant in replication 
analysis using the linkage disequilibrium-thinned SNP list indicating that the primary GSEA 
signals were not being driven by strongly correlated SNPs in closely spaced genes 
(Supplementary Table S3). All six networks were also significantly associated (P = 0.03 to 
4×10−4) with serous EOC risk in replication analysis using the independent COGS data set 
(Supplementary Table S4). Next, we observed that 33 genes were shared by more than one 
of the six networks. Further, 18 genes across the six networks were located less than 1 Mb 
from the most significantly-associated SNPs at the 2q31 and 17q21.32 risk loci. To 
eliminate potential inflation of the GSEA signal due to genes co-expressed locally with the 
hub TF genes anchoring the significant networks, we pooled the 249 genes in the six 
original networks and removed the 18 genes at 2q31 and 17q21.32. We also counted the 
overlapping genes only once in the pooled network. The result was a set of 174 genes of 
which 170 were covered by SNPs in the COGS data set. This filtered set was also 
significantly associated with serous EOC risk in GSEA using the ranked gene list derived 
from the COGS data (P = 0.007). A secondary GSEA run with less stringent parameters that 
allowed inclusion of the 24 co-expression networks with more than 10 genes (including the 
10 previously excluded networks containing > 500 genes) did not identify any additional 
significant networks at the P < 0.05 and FDR < 0.05 threshold (Supplementary Table S5). 
Supplementary Table S6 shows differences in the number of genes from the TCGA data set 
covered by intragenic SNPs in the ranked lists generated from the GWAS meta-analysis, 
LD-thinned, and COGS data sets.
Given that all networks significant in the primary analysis were centered on hub TFs from 
the HOX gene family and the observation that some of their targets were shared, we merged 
the leading edge subsets (i.e., the genes underlying the GSEA signal) from each of the six 
networks. This yielded a combined network of 50 non-redundant genes most strongly 
associated with serous EOC risk and 81 interactions between them (Figure 2). The 50 genes 
were submitted as input to the web-based tool, DAPPLE, to determine if they demonstrate 
significant connectivity at the protein-protein interaction (PPI) level, a frequent 
characteristic of disease associated networks (38). DAPPLE connected the proteins encoded 
by the genes using a database of high-confidence PPIs, allowing for connections between 
input genes/proteins that were either direct or indirect via a single intermediate protein not in 
the input group. Two PPI networks were formed (Supplementary Figure S2), with the larger 
network involving 29 of the 50 input genes/proteins. Compared to 10,000 permuted 
networks with similar underlying topology, the input proteins were more likely to be 
connected to each other indirectly (through a single intermediate protein) than expected by 
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chance alone (P = 0.01). Next, we evaluated whether the genes co-expressed with the hub 
TF genes in the combined network were more likely to be among the genes most strongly 
co-expressed with the same TFs in an independent microarray data set from the Australian 
Ovarian Cancer Study. All interactions in the combined network between a hub TF gene and 
another HOX cluster gene and 25/44 (57%) hub TF and non-HOX cluster gene interactions 
were among the top 10% of interactions for the corresponding hub TF in the AOCS data set 
(for HOX non-HOX interactions, binomial test P = 2×10−14). In fact, 32/37 (86%) HOX-
HOX and 13/44 (30%) HOX-non-HOX interactions were seen at a more stringent top 1% 
level (for HOX non-HOX interactions, binomial test P = 4×10−16). HOX-HOX interactions 
were analyzed separately since HOX cluster members are already known to interact with 
each other (39). Finally, we assessed enrichment of known TF binding motifs up to 1 kb 
upstream of the 40 non-HOX cluster genes in the combined network using the online tool 
PSCAN to look for possible overrepresentation of the few homeodomain motifs that are well 
established. The binding motif for the cooperative homeodomain TFs, HOX-A9-MEIS1, 
was the second most overrepresented among the 40 non-HOX cluster genes in the combined 
network (P = 0.008), second only to the motif for SPZ1 (P = 0.006). Thus, the AOCS data 
set and the PSCAN tool further supported the TF-target gene interactions observed in the 
combined network.
Discussion
In this study, we used network analysis to integrate TCGA gene expression data with 
GWAS meta-analysis summary findings to identify six networks significantly associated 
with serous EOC risk and replicated our results using the independent COGS data set. 
Network construction was guided by the premise that TF genes near genome-wide 
significant serous EOC risk SNPs may be the functional targets of these SNPs. The TFs may 
regulate pathways of target genes, represented by genes strongly co-expressed with each TF 
gene that are, in turn, enriched for SNPs nominally associated with serous EOC 
susceptibility. The product of the multi-step analysis presented here is a combined network 
of 50 genes and 81 interactions (Figure 2). A significant proportion of these interactions 
were further supported by co-expression analysis in the independent AOCS microarray data 
set.
Hub TF genes of the six significant networks and the genes in their combined network 
suggest that specific members of the HOXD and HOXB clusters potentially mediate the 
effects of the 2q31 and 17q21.32 serous EOC risk loci, respectively. While this analysis was 
ongoing, a parallel comprehensive functional follow-up of the 2q31 locus revealed that 
SNPs at this locus impact serous EOC development through HOXD9 (Lawrenson et al., 
submitted). HOXD9 could not be evaluated as a hub TF using GSEA since its network 
contained just six genes (including HOXD1 and HOXD3) at the stringent cut-off we used for 
identifying only the most strongly co-expressed genes. However, it is worth noting that 
HOXD9 is a leading edge or core member of two of the significant networks identified 
(centered on HOXD1 and HOXD3) and therefore appears in the combined network 
uncovered by this analysis (Figure 2). Thus, HOXD9 may have a putative master regulatory 
role upstream of HOXD1 and HOXD3 in serous EOC development. At 17q21.32, HOXB5, 
HOXB6 and HOXB7 have collectively been implicated in early carcinogenic reprogramming 
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of transcription in epithelial cells (40). HOXB7 is also known to be involved in DNA repair 
catalyzed by poly(ADP-ribose) polymerase (41). HOXB7 expression is elevated in ovarian 
cancer and overexpression is associated with marked proliferation of immortalized normal 
ovarian surface epithelial cells by upregulation of basic fibroblast growth factor (42). 
Hypermethylation of HOXB5, a possible tumor suppressor, is also a frequent somatic change 
reported in ovarian cancer and corresponding in vitro models (43). Overall, the identification 
of a novel HOX-centric pathway is consistent with the emerging role of developmental 
genes in ovarian carcinogenesis (44). Other members of the HOX gene family have 
previously been shown to guide both reproductive tract patterning during early development 
and epithelial ovarian cancer cellular morphology (45).
A striking feature of the combined network is that it connects genes at five of the 12 
genome-wide significant serous EOC risk loci. This is particularly compelling because only 
TF genes from two of these loci (2q31 and 17q21.32) were used as seed hubs for the six 
significant networks that underlie the combined network. The other three were picked up by 
the combination of co-expression and enrichment analysis, that is, without any a priori 
input. A small number of genes contribute to the combined network from the three non-hub 
loci in this group of five: BNC2 (HOXD1 network member) at 9p22; HNF1B (HOXB6 and 
HOXB7 networks) and LHX1 (HOXD1 network) at 17q12; and ABHD8 (HOXB7 network) at 
19p13. Serous EOC risk SNPs at 17q12 have previously been associated with significantly 
higher HNF1B methylation (46). Likewise, the SNPs at the 9p22 risk locus are likely to 
represent multiple transcriptional regulatory elements acting on BNC2 based on an 
integrated functional analysis (Buckley et al., in preparation). Finally, functional work on 
19p13 indicates that ABHD8 is the most likely target of serous EOC and breast cancer risk 
SNPs at this locus (Lawrenson et al., in preparation) (4,47). Taken together, these findings 
for ABHD8, HNF1B and BNC2 underscore the power of integrating GWAS with tissue-
specific gene expression data in a network paradigm to prioritize the genes likely to be 
regulated by genome-wide significant risk variants for downstream functional 
characterization (23).
The addition of orthogonal biological priors to statistical evidence from GWAS may also 
unravel interesting targets at loci that are nominally significant but fail to reach genome-
wide significance. For example, the oncogene WT1 that appears in the combined network is 
a highly specific serous ovarian lineage marker (48). The top SNP in this gene has P = 0.012 
in the GWAS meta-analysis that strengthens to P = 0.0078 in the COGS data set. However, 
while it is intriguing to identify such possible functional targets associated with serous EOC 
susceptibility, it will require extensive experimental validation to confirm their role in 
disease predisposition. Profiling of the relevant HOXB and HOXD transcription factor 
binding in fallopian tube and ovarian surface epithelial cells and in ovarian cancer cells may 
identifying binding sites containing serous EOC risk SNPs analogous to what has been done 
to establish the role of other TFs in breast cancer susceptibility (49,50). The emergence of 
genome editing technologies such as the CRISPR-Cas9 system may further enable 
modification of risk SNPs in these HOX binding sites to modulate and confirm the role of 
the HOX target genes in cellular models that reflect early stages of ovarian cancer (51).
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The observation that 29 of the 50 genes in the combined network were also part of a protein-
protein interaction network with significant indirect connectivity suggests that this gene 
network is biologically coherent. The failure to capture the remaining 21 co-expressed genes 
in the PPI network also hints that some interactions are perhaps tissue-specific and/or 
specific to the transcriptome since DAPPLE, the tool used for the PPI network analysis, 
relies on protein interactions found in different tissues (33).
There are limitations inherent in this study. GSEA is optimized to detect enrichment in gene 
sets or networks containing between 15 and 500 genes. Although we applied it to the 10 
networks containing more than 500 genes in a secondary analysis, our failure to detect any 
additional significant networks among the very large networks does not rule out the presence 
of genuine enrichment in these networks. Co-expression is likely not the perfect proxy for 
defining TF targets and the risk locus-TF gene and TF-target gene interactions suggested by 
this analysis warrant follow-up.
In conclusion, by identifying a HOX-centric gene co-expression network associated with 
serous EOC risk, this report highlights the potential of network analysis to combine GWAS 
with other molecular data to offer insights into the mechanisms linking population studies 
with cancer biology.
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Figure 1. 
Outline of steps involved in the integrated analysis of GWAS and tissue-specific expression 
data sets to identify, replicate and computationally follow-up gene networks associated with 
serous EOC susceptibility.
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Figure 2. 
Cytoscape visualization of the combined network. Hub TF genes of the six significant 
networks underlying the combined network are outlined in green. Candidate genes at 
genome-wide significant risk loci other than the input hub loci (2q31 and 17q21.32) are 
outlined in blue. Nodes are colored according to the P-value of the most significant 
intragenic SNP in the GWAS meta-analysis (uncorrected for the number of intragenic 
SNPs). Diamond shaped genes have P < 0.05 after applying the modified Sidak correction.
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